obesity drug news today glp-1 oct 27 2025 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs More GLP-1 news: in a
Description
95% CI: 0.581.14)
The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence
An analysis of PBM tension, the Newkirk litigation, Anthems GLP-1 coverage issues, and emerging risks in pharmacy benefit plan design.
They should only be used under the supervision of a qualified healthcare provider
Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions
Keep an open mind, but not so open that your brains fall out. Richard P
